Iowa House Bill HSB616

Iowa 2023-2024 Regular Session

• Introduced: 1/25/24
• Refer: 1/25/24

Caption

A bill for an act relating to the ordering and administering of epinephrine auto-injectors for persons ages eighteen years and older by a pharmacist pursuant to statewide protocols.

Impact

If passed, HSB616 would significantly amend Section 155A.46 of the Iowa Code, which currently governs the practice of pharmacists in similar contexts. By allowing pharmacists to administer epinephrine auto-injectors without a prescription, the bill aims to enhance response capabilities in instances of anaphylactic shock. It is expected to streamline the process for individuals who may require immediate treatment, thereby improving overall public health responses to allergic reactions. The requirement for pharmacists to maintain records and inform primary care providers ensures a degree of accountability and continuity of care.

Summary

House Study Bill 616 (HSB616) aims to modify the existing regulations regarding the ordering and administering of epinephrine auto-injectors by pharmacists. Under the proposed law, pharmacists would be authorized to order and administer these auto-injectors to individuals aged 18 years and older without requiring a prescription. The bill outlines that this action must be conducted following statewide protocols developed in collaboration with the board of pharmacy and the Department of Health and Human Services. This initiative reflects a growing recognition of the need for quick access to life-saving medications, particularly in emergency situations arising from severe allergic reactions.

Contention

Notable points of contention surrounding HSB616 include the responsibilities placed on pharmacists regarding record-keeping and the communication protocol with primary care providers. While supporters of the bill argue that it empowers pharmacists and enhances community healthcare, there are concerns raised about the adequacy of training for pharmacists to handle such emergencies effectively. Opponents may fear that this change might lead to an influx of patients seeking epinephrine without proper medical oversight, which could complicate patient management and healthcare resource allocation.